Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases

作者：Krisna C. Duong‐Ly, Karthik Devarajan, Shuguang Liang, Kurumi Y. Horiuchi, Yuren Wang, Haiching Ma, Jeffrey R. Peterson · 发表于：Cell Reports · 年份：2016 · DOI：10.1016/j.celrep.2015.12.080 · 被引用次数：45 · 研究领域：Lung Cancer Treatments and Mutations、HER2/EGFR in Cancer Research、Colorectal Cancer Treatments and Studies

Small-molecule kinase inhibitors have typically been designed to inhibit wild-type kinases rather than the mutant forms that frequently arise in diseases such as cancer. Mutations can have serious clinical implications by increasing kinase catalytic activity or conferring therapeutic resistance. To identify opportunities to repurpose inhibitors against disease-associated mutant kinases, we conducted a large-scale functional screen of 183 known kinase inhibitors against 76 recombinant mutant kinases. The results revealed lead compounds with activity against clinically important mutant kinases, including ALK, LRRK2, RET, and EGFR, as well as unexpected opportunities for repurposing FDA-approved kinase inhibitors as leads for additional indications. Furthermore, using T674I PDGFRα as an example, we show how single-dose screening data can provide predictive structure-activity data to guide subsequent inhibitor optimization. This study provides a resource for the development of inhibitors against numerous disease-associated mutant kinases and illustrates the potential of unbiased profiling as an approach to compound-centric inhibitor development.